33142-21-1

Basic information

• Product Name: ethyl (chloroformyl)acetate
• Synonyms: 2-Chloro-3-oxopropanoic acid ethyl ester;2-Chloro-3-oxopropionic acid ethyl ester;Ethyl 2-Chloro-3-oxopropanoate;Propanoic acid, 2-chloro-3-oxo-, ethyl ester;Ethyl α-ForMyl-α-chloroacetate;Ethyl 2-chloro-2-formylethanoate, Ethyl 2-chloro-3-oxopropionate;Ethyl 2-chloro-3-oxopropanoate, tech;2-chloro-3-oxopropanoate
• CAS NO: 33142-21-1
• Molecular Formula: C₅H₇ClO₃
• Molecular Weight: 150.56
• EINECS: 251-390-6
• Product Categories: Miscellaneous Reagents
• Mol File: 33142-21-1.mol

Chemical Properties

• Melting Point: 88-90 °C(Solv: benzene (71-43-2))
• Boiling Point: 172.5°Cat760mmHg
• Flash Point: 68.2°C
• Appearance: /
• Density: 1.217 g/cm³
• Vapor Pressure: 1.34mmHg at 25°C
• Refractive Index: 1.431
• Storage Temp.: Hygroscopic, -20°C Freezer, Under Inert Atmosphere
• PKA: 4.09±0.29(Predicted)
• Stability: Store FROZEN
• CAS DataBase Reference: ethyl (chloroformyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl (chloroformyl)acetate(33142-21-1)
• EPA Substance Registry System: ethyl (chloroformyl)acetate(33142-21-1)

Safety Data

• Hazardous Substances Data: 33142-21-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl (chloroformyl)acetate is used as an intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its reactivity allows for the creation of new molecules with potential therapeutic properties.
Used in Chemical Synthesis:
Ethyl (chloroformyl)acetate is used as a reagent in chemical synthesis for [application reason]. Its ability to react with a variety of other compounds makes it a versatile building block in the creation of new molecules with specific properties.
Used in Research and Development:
Ethyl (chloroformyl)acetate is used as a research compound for [application reason]. Its unique properties and reactivity make it an interesting subject for studying new reaction mechanisms and exploring its potential in various applications.
When diluted to 5% in benzene, Ethyl (chloroformyl)acetate can be more easily handled and utilized in various applications, making it a valuable material in the fields of pharmaceuticals, chemical synthesis, and research and development.

InChI:InChI=1/C5H7ClO3/c1-2-9-5(8)3-4(6)7/h2-3H2,1H3

Upstream product

• 1001-26-9 ethyl 3-ethoxyacrylate 
• 64-17-5 ethanol 
• 105-39-5 chloroacetic acid ethyl ester 
• 109-94-4 formic acid ethyl ester 
• 1027194-45-1 potassium (1E)-2-chioro-3-ethoxy-3-oxoprop-1-en-1-olate 

Downstream Products

• 78442-10-1 5-Carbethoxy-2-(N-carbophenoxy-N-methylamino)methylthiazole 
• 1206706-50-4 ethyl 2-(2-methyl-3-nitrophenyl)-4-(4-(morpholine-4-carbonyl)phenylamino)imidazo[1,2-f][1,2,4]triazine-7-carboxylate 
• 1134327-98-2 7-bromoimidazo[1,2-a]pyridin-3-carboxylate ethyl ester 
• 1313410-31-9 ethyl 6-cyanoimidazo[1,2-a]pyridine-3-carboxylate 
• 1313408-99-9 ethyl 7-fluoroimidazo[1,2-a] pyridine-3-carboxylate 
• 1609165-62-9 ethyl 8-[(2,6-difluorobenzyl)oxy]imidazo[1,2-a]pyridine-3-carboxylate 
• 893444-26-3 C₁₆H₁₈N₂O₄S 
• 304696-11-5 2-(3-benzyl-ureido)-oxazole-5-carboxylic acid ethyl ester 
• 959967-24-9 ethyl 2-anilino-1,3-oxazole-5-carboxylate 
• 736971-43-0 ethyl 2-[(2,6-dichlorophenyl)methyl]-1,3-thiazole-5-carboxylate 
• 113853-16-0 2-amino-oxazole-5-carboxylic acid ethyl ester 
• 18227-18-4 benzimidazole hydrochloride 
• 105-39-5 chloroacetic acid ethyl ester 
• 99853-81-3 ethoxycarbonylchloroacetaldehyde 2,4-dinitrophenylhydrazone 

Relevant articles and documents

Thiazole derivative and synthesis method thereof

The invention belongs to the technical field of organic synthesis, particularly relates to a thiazole derivative and a synthetic method thereof, and particularly relates to a thiazole derivative (Z)-4-((2-(2-(2-(2,5-dimethoxyphenyl)-thiazole-5-yl)-ethylimino)(phenyl)methyl)-1,3-benzenediol and a synthetic method thereof. The synthesis method provided by the invention comprises the following steps:by taking 2,5-dimethoxybenzamide and ethyl 2-chloroacetate as raw materials, carrying out six reaction steps of carbonyl sulfide reaction, substitution, cyclization, substitution, chlorination, cyanidation, amidation, hydrolysis and substitution reaction to prepare the (Z)-4-((2-(2-(2-(2,5-dimethoxyphenyl)-thiazole-5-yl)-ethylimino)(phenyl)methyl)-1,3-benzenediol. According to the invention, an efficient synthesis method is provided for the synthesis of the thiazole derivative.

Benzo [d] [1, 3] oxathiol, benzo [d] [1, 3] benzo [d] [1, 3] oxathiol 3 - oxide or 3, 3 - dioxide compounds and G protein-coupled receptor 119 oxathiol action of number as method/use

There are provided compounds containing benzo[d][1,3]oxathiole, benzo[d][1,3]oxathiole 3-oxide, and benzo[d][1,3]oxathiole 3,3-dioxide, as well as uses/methods related thereto, including treatment of diseases and condition associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders.

COMPOUNDS CONTAINING POLYSUBSTITUTED BENZO[D][1,3]OXATHIOLE, BENZO[D][1,3]OXATHIOLE 3-OXIDE OR BENZO[D][1,3]OXATHIOLE 3,3-DIOXIDE AND METHODS/USES THEREOF AS AGONISTS OF G PROTEIN-COUPLED RECEPTOR 119

There are provided compounds having formula (I), in which: X1 and X2 are selected from certain combinations of O, S, SO and SO2; X3 is selected from CH, CF and N; X4 is selected from CH and N; X6, X6' and X6'' are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, and amide groups; X7 and X7' are selected from H, halogen, and certain alkyl, haloalkyl, alkoxy, hydroxyalkyl, aminoalkyl and amide groups, or both X7 and X7' together form a cycloalkyl or heterocycle; and A is selected from certain optionally substituted, alkoxy, piperazinyl and pyrrolidinyl groups. Also provided are compositions comprising these compounds, as well as uses/methods related thereto, including treatment of diseases and conditions associated with GPR119 dysregulation, Type 2 diabetes mellitus, and related metabolic disorders. (I)

CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME

The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.

FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR

The present invention discloses a five-membered heterocyclic amide WNT pathway inhibitor, which belongs to a compound that regulates the activity of a Wnt signaling pathway, and provides a method for preparing such a compound, and the use of such a compound in preparing a medicament that antagonizes the Wnt signaling pathway. The five-membered heterocyclic amide WNT pathway inhibitor provided by the invention has a remarkable anti-tumor activity based on a target-based rational drug design of, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

Heteroatom-Interchanged Isomers of Lissoclinamide 5: Copper(II) Complexation, Halide Binding, and Biological Activity

Cyclic peptides, especially those produced by marine cyanobacteria symbionts, are considered to play an important ecological role in host defence. Chemists have long compared the cyclic peptide cavitand architecture with that of macrocyclic ligands, and proposed that they mediate metal-ion transport. The study presented herein investigated the metal chelation of non-natural heteroatom-interchanged (HI) isomers of lissoclinamide 5, by using MS, EPR, and DFT calculations. The latter identified three possible structures for the CuII complex with natural lissoclinamide 5, with the most likely determined to be that with the metal ion bound through the nitrogen donors of the thiazoles and one deprotonated amide. For HI-lissoclinamide 5 the calculations suggest that the CuII ion is bound in a bidentate manner by the oxazoline nitrogen atom and one deprotonated amide nitrogen atom, with the S donor of the thiazole not involved in coordination. Along with evidence of copper binding these systems also bound halide ions. Evaluation of the anti-cancer properties demonstrated that the biological activity of HI-lissoclinamide 5 against T24 bladder cells was eleven-fold lower as compared to natural lissoclinamide 5. Addition of a CuII salt had no effect on the activity of lissoclinamide 5. Overall, this comprehensive study of the HI concept has demonstrated that small changes propagate dramatic effects in complexation, halide binding, and biological activity.

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

HEPATITIS B CORE PROTEIN MODULATORS

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:

PROCESS FOR MAKING HEPATITIS B CORE PROTEIN MODULATORS

The present disclosure provides, in part, a process for preparing compounds (I) having allosteric effector properties against Hepatitis B virus Cp.

CK2 INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. For Formula (I) compounds R1, R2, R3, Ar and Z are as defined in the specification. The inventive Formula (I) compounds are inhibitors of CK2 and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer, inflammation and immunological disorders.